BlackRock Health Sciences:BME

    Manage Alerts


    As of 10/23/2020

    52 Wk Avg$41.12$40.551.38%
    52 Wk High$44.99$44.426.47%
    52 Wk Low$27.00$30.41-8.91%
    Regular Distribution TypeManaged Distribution
    Distribution Rate5.50%
    Distribution Amount$0.2000
    Distribution FrequencyMonthly
    Past performance is no guarantee of future results.

    Basic Information

    Investment Objective

    Under normal market conditions the Fund will invest at least 80% if its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. The Fund will consider a company to be principally engaged in a health science or related industry if 50% or more of its revenues are derived from, or 50% or more of its assets are related to, its health sciences business. Although the Trust generally will invest in companies included in the Russell 3000 Index, the Trust may invest in equity securities of health sciences companies with any size market capitalisation, including small and min-cap health sciences companies and companies that are not in the Russell 3000 Index. The Trust may invest up to 20% of its total assets in other investments. These investments may include equity and debt securities of companies not engaged in the health sciences industry. The Trust reserves the right to invest up to 10% of its total assets in non-investment grade debt securities.

    Capital Structure

    As of 10/23/2020

    Total Investment Exposure:$499.025M
    Total Common Assets:$499.014M
    Common Shares Outstanding:11,516,598
    Annual Expense Ratios

    As of 12/31/2019

      Per Common Share
    Management FeesN/A
    Other Expenses:N/A
    Baseline Expense: N/A
    Interest Expense:N/A
    Total: 1.09%
    Fund Management

    Fund Sponsor

    Portfolio Managers
    Christopher M. Accettella, Erin Xie, Kyle McClements

    Category: Equity-Sector Equity
    Ticker: BME
    NAV Ticker: XBMEX
    Average Daily Volume (shares): 43,108
    Average Daily Volume (USD): $1.738M
    Inception Date: 3/28/2005
    Inception Share Price: $25.00
    Inception NAV: $23.83
    Tender Offer: No
    Term: No
    Fiscal Year End: December 31
    Third Party Links & Reports


    As of 10/23/2020

    Past performance is no guarantee of future results.
    Distribution History

    Enter declared start and end dates to display distribution history below. Income, Long Gain, Short Gain and ROC breakdowns will only be shown for the past year.

    Declared Date Payable Date Ex Date Distrib Amount Income Long Gain Short Gain ROC

    *Indicates a Special Distribution: A distribution disbursed in addition to the normal distributions paid out by the company.

    Key Information Regarding Distributions
    Avg. Earnings Per Share:
    As of 6/30/2020
    Annualized Distribution Rate on NAV:
    As of 10/23/2020
    Total Return on NAV (12 months):
    As of 10/23/2020
    Total % Portfolio Effectively Leveraged:
    As of 10/23/2020

    Pricing Information

    Premium/Discount Information
    Past performance is no guarantee of future results.
    Premium/Discount Information

    As of 10/23/2020

    PeriodAvg Discount
    6 Month1.30%
    1 Year1.38%
    3 Year2.07%
    5 Year3.07%

    As of 10/23/2020

    3 Month-0.05
    6 Month-0.55
    1 Year-0.46
    Pricing History
    Date NAV Premium / Discount


    Calendar Year Total Returns

    As of 9/30/2020
    Category: Morningstar US CEF Sector Equity

    Past 20 Years

    Return YearPriceNAVCategory - PriceCategory - NAV
    Past performance is no guarantee of future results.
    Annualized Total Returns

    Returns for periods less than one year are cumulative rather than annualized

    As of 9/30/2020
    Category: Morningstar US CEF Sector Equity

    Past performance is no guarantee of future results.

    Portfolio Characteristics

    Portfolio Characteristics
    Number of Holdings:
    As of 6/30/2020
    Annual Portfolio Turnover:
    As of 12/31/2019
    Asset Allocation

    As of 6/30/2020 reported by Fund Sponsor

    Top Sectors

    As of 6/30/2020 reported by Fund Sponsor

    Defensive (Super Sector)98.92%
    Cash Equivalents0.96%
    Cash Equivalents (Super Sector)0.96%
    Cyclical (Super Sector)0.58%
    Basic Materials0.47%
    Financial Services0.11%
    Top Holdings

    As of 6/30/2020 reported by Fund Sponsor

    HoldingValue% Portfolio
    UnitedHealth Group Inc$34.00M7.22%
    Johnson & Johnson$22.17M4.71%
    Abbott Laboratories$21.58M4.58%
    Amgen Inc$13.94M2.96%
    Thermo Fisher Scientific Inc$13.47M2.86%
    Medtronic PLC$12.90M2.74%
    Boston Scientific Corp$12.85M2.73%
    Eli Lilly and Co$12.46M2.65%
    Vertex Pharmaceuticals Inc$12.10M2.57%
    Humana Inc$11.55M2.45%
    Country Allocation

    As of 6/30/2020 reported by Fund Sponsor

    Country% Portfolio
    United States - Equity89.45%
    Switzerland - Equity2.34%
    China - Equity2.09%
    France - Equity2.08%
    Denmark - Equity1.36%
    United Kingdom - Equity0.79%
    Germany - Equity0.62%
    Japan - Equity0.51%
    Belgium - Equity0.24%

    Closed-end fund historical distribution sources have included net investment income, realized gains, and return of capital. For more detailed information on the distributions of a specific fund, please visit the sponsor's website.


    Distribution type sourced from Morningstar. In general, managed distributions may be sourced from net investment income, realized gains and return of capital. does not undertake to disclose specific information about closed-end fund distribution sources. For specific information about a fund's distribution sources, visit the fund sponsor's website.

    The following information applies to closed-end funds in general: Fund shares are not guaranteed or endorsed by any bank or other insured depository institution, and are not federally insured by the Federal Deposit Insurance Corporation. Shares of closed-end funds are subject to investment risks, including the possible loss of principal invested. There can be no assurance that fund objectives will be achieved. Closed-end funds frequently trade at a discount to their net asset value. NAV returns are net of fund expenses, and assume reinvestment of distributions.